FDA approves the investigator-sponsored clinical trial (IST) of HMBD-002 in combination with venetoclax and azacitidine in AML and MDS
Percheron’s CEO and MD, Dr Michael Baker, commented: “AML remains a devastating disease for many patients despite significant advances in treatment. With a five-year relative survival rate of approximately 33% there remains a clear need for new therapeutic approaches that can improve outcomes for patients. The Vanderbilt study provides an exciting opportunity to evaluate HMBD-002 in combination with venetoclax and azacitidine, two established AML therapies, and investigate whether targeting VISTA can further Page 2 of 3 improve therapeutic outcomes. With HMBD-002 manufactured for the study and the FDA regulatory clearance now received, we are very pleased with the progress towards commencing this important clinical study.”
Share:
More News
“We’ve already seen what subcutaneous amivantamab may offer patients with head and neck cancer after their disease has progressed. Now, we see the potential impact of using this approach earlier in recurrent or metastatic disease,” said Yusri Elsayed, M.D., M.H.Sc., Ph.D., Global Therapeutic Area Head, Oncology, Johnson & Johnson. “Our
“Meaningful progress has been made in the treatment of pancreatic cancer and we are proud that Tumor Treating Fields therapy is one of the new options available to patients. However, advanced pancreatic cancer remains one of the most difficult cancers to treat,” said Uri Weinberg, MD, PhD, Chief Medical and
“We see anal cancer as the starting point for building a pelareorep plus checkpoint inhibitor platform across HPV-driven cancers,” said Jared Kelly, Chief Executive Officer of Oncolytics. “Our survival data and recent FDA regulatory clarity give us a path to pursue registration in anal cancer while expanding into other HPV-associated
“Multiple myeloma is a chronic blood cancer that can reshape a person’s life. Patients deserve therapeutic options that are not only effective, but also support the realities of when, where and how they receive treatment,” said Daejin Abidoye, M.D., vice president and therapeutic area head, oncology, solid tumor and hematology,